<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549795</url>
  </required_header>
  <id_info>
    <org_study_id>2372P</org_study_id>
    <nct_id>NCT01549795</nct_id>
  </id_info>
  <brief_title>Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy</brief_title>
  <official_title>Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera di Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm pilot clinical trial. Patients with non operable CC associated with PSC will be
      subjected to liver transplantation after a neoadjuvant multimodal therapy protocol.

      Cholangiocarcinoma (CC) accounts for 3% of all gastrointestinal cancers; it is more frequent
      in patients with primary sclerosing cholangitis (PSC), who carry an 8%-12% risk of developing
      this type of neoplasm. Only a minority of patients are suitable for resection partly because
      of the anatomic position of the tumor (which often arises from the bile duct bifurcation) and
      partly because of the frequently coexisting liver disease. In fact, CC is currently
      considered a major contraindication to liver transplantation (OLT) at the majority of
      centers, given a 5-year survival rate of 0%-35%.

      New strategies have been developed for the treatment of this kind of cancer arising in PSC.
      The Nebraska University group showed a 1 and 3 years survival of 55 and 45 % combining a
      neoadjuvant intra bile duct barchytherapy and 5-FU based chemotherapy with liver
      transplantation. University of Pittsburg proposed also a neoadjuvant protocol prior to liver
      transplantation based on systemic chemotherapy and external radiotherapy reporting a 53% 5
      years survival. More convincing results come from the Mayo Clinic. An accurate selection of
      patients and a proper neoadjuvant multimodal therapy (chemotherapy, external radiotherapy and
      intraluminal bile duct brachytherapy) lead to a 80% 5 years survival after liver
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients free of disease at 24 months post-transplant</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to recurrence after liver transplant</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression disease free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall 2 years survival after liver transplantation</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate due to radiotherapy (Hepatic artery thrombosis and Portal vein thrombosis)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Hilar Cholangiocarcinoma</condition>
  <condition>Primary Sclerosing Cholangitis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver transplantation</intervention_name>
    <description>Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>45 Gy external radiations</intervention_name>
    <description>45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Endoluminal bile duct Brachytherapy</intervention_name>
    <description>Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine - administered till liver transplantation</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pre liver transplantation laparoscopic hand assisted staging</intervention_name>
    <description>Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years

          -  Male or female

          -  Diagnosis of Cholangiocarcinoma using:

          -  PTBD biopsy or Brushing cytology

          -  Ca 19-9&gt;100mg/ml and/or liver mass at CT or MRI with malignant stenosis apperance at
             Cholangiography,

          -  Non resectable tumour araising above the cystic duct

          -  Absence of intra and extra hepatic metastasis

          -  ECOG score(Eastern Cooperative Oncology Group) 0

          -  ASA score (American Society of Anesthesiologists) â‰¤ 3

          -  Ability to understand and willingness to sign the written informed consent form (ICF)

        Exclusion Criteria:

          -  Intrahepatic Cholangiocarcinoma

          -  Non controlled infection

          -  Previous radio or chemotherapy

          -  Previsous bile duct resection or attempt to resection

          -  Intra and/or extrahepatic metastasis

          -  Preivious malignant neoplasm (within 5 years)

          -  Execution of trans peritoneal biopsy

          -  Tumour diameter more than 3 cm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Cillo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enrico Gringeri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Umberto Cillo, MD</last_name>
    <phone>+390498218547</phone>
    <email>cillo@unipd.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Gringeri, MD</last_name>
    <phone>+390498218547</phone>
    <email>enrico.gringeri@unipd.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Cillo, MD</last_name>
      <phone>+390498218547</phone>
      <email>cillo@unipd.it</email>
    </contact>
    <contact_backup>
      <last_name>Enrico Gringeri, MD</last_name>
      <phone>+390498218547</phone>
      <email>enrico.gringeri@unipd.it</email>
    </contact_backup>
    <investigator>
      <last_name>Umberto Cillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Gringeri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Domenico Bassi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacomo Zanus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniele Neri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco D'Amico, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Vitale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fegatochirurgia.com</url>
    <description>Hepatobiliary surgery and Liver Transplantation Unit, University Hospital of Padua (Italy)</description>
  </link>
  <reference>
    <citation>Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005 May;241(5):693-9; discussion 699-702.</citation>
    <PMID>15849505</PMID>
  </reference>
  <reference>
    <citation>Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61.</citation>
    <PMID>16135931</PMID>
  </reference>
  <reference>
    <citation>Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010 Jul;23(7):692-7. doi: 10.1111/j.1432-2277.2010.01108.x. Epub 2010 May 20. Review.</citation>
    <PMID>20497401</PMID>
  </reference>
  <reference>
    <citation>Hamilton JP. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics. 2010 Apr 1;2(2):233-243.</citation>
    <PMID>20556199</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Padova</investigator_affiliation>
    <investigator_full_name>Prof. Umberto Cillo</investigator_full_name>
    <investigator_title>Director of the Hepatobiliary Surgery and Liver Transplantation Unit</investigator_title>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Neoadjuvant radio- chemo-therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

